Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how

This article was originally published in The Pink Sheet Daily

Executive Summary

Global players need to consider offering assistance in China, where most patients pay nearly 50 percent of their medical expenses out of pocket, and most simply cannot afford brand name innovative oncology drugs.

You may also be interested in...

China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected

SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies

Bayer Shifting Further To Emerging Markets Including China

Already a big player in the world's largest pharmemerging market, China, Bayer is plunging deeper and reallocating more resources in capital investment and manpower to emerging markets

Building A New Model For Developing New Therapies: An Interview With AstraZeneca's Strategic Alliance Asia Director Richard Wang

Although AstraZeneca is paring down its pipeline by halting discovery efforts in 10 specific diseases, which account for 25 percent of the total diseases that earlier drove research by AstraZeneca ("The Pink Sheet" Daily, March 2, 2010), it won't stop R&D expansion plans in China. As big pharmaceutical firms compete to find the next generation of innovative drugs, translational science may help companies to find the right drug for the right patient and bring these medicines to market faster. During the recent Asia Pharma R&D Leaders conference in Shanghai, Richard Wang, AstraZeneca's Director of Strategic Alliances - Asia, sat down with PharmAsia News' Shanghai Bureau to discuss the strategy of AstraZeneca's Innovation Center China and how translational science is helping the company develop new compounds.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts